Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1971 1
1992 1
1995 2
1996 2
1998 3
1999 4
2000 4
2002 4
2004 2
2005 1
2006 1
2007 6
2008 4
2009 7
2010 14
2011 6
2012 6
2013 6
2014 8
2015 3
2016 8
2017 14
2018 7
2019 17
2020 15
2021 13
2022 21
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Colombel JF, et al. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492. N Engl J Med. 2010. PMID: 20393175 Free article. Clinical Trial.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
Fulminant colitis.
Portela F, Lago P. Portela F, et al. Best Pract Res Clin Gastroenterol. 2013 Oct;27(5):771-82. doi: 10.1016/j.bpg.2013.08.011. Epub 2013 Sep 6. Best Pract Res Clin Gastroenterol. 2013. PMID: 24160933 Review.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Early intervention with biologic therapy in Crohn´s disease: how early is early?
Revés J, Mascarenhas A, José Temido M, Morão B, Neto Nascimento C, Rita Franco A, Mendes RR, Palmela C, Chagas C, Figueiredo PN, Glória L, Portela F, Torres J. Revés J, et al. Among authors: portela f. J Crohns Colitis. 2023 Nov 24;17(11):1752-1760. doi: 10.1093/ecco-jcc/jjad089. J Crohns Colitis. 2023. PMID: 37220397
Reply to the letter to the Editor.
Urso S, Sadaba R, González JM, Nogales E, Pettinari M, Tena MÁ, Paredes F, Portela F. Urso S, et al. Among authors: portela f. J Card Surg. 2020 Jun;35(6):1394. doi: 10.1111/jocs.14565. Epub 2020 Apr 19. J Card Surg. 2020. PMID: 32306428 No abstract available.
Protein-losing enteropathy: is it Crohn's disease?
Temido MJ, Lopes S, Figueiredo P, Portela F. Temido MJ, et al. Among authors: portela f. Rev Esp Enferm Dig. 2024 Apr 30. doi: 10.17235/reed.2024.10461/2024. Online ahead of print. Rev Esp Enferm Dig. 2024. PMID: 38685896 Free article.
181 results